The following table summarizes the Company’s stock option activity under the Pre-IPO Plan since December 31, 2025:


	Number of Shares	Weighted- Average Exercise Price
Outstanding as of December 31, 2025	24,089,219	$	1.07
Granted	–	–
Exercised	(2,862,389)	0.27
Forfeited	–	–
Outstanding as of June 30, 2026	21,226,830	$	1.18
Options exercisable as of June 30, 2026	21,226,830	$	1.18

The following table summarizes the Company’s stock option activity under the 2020 Plan since December 31, 2025:


	Number of Shares	Weighted- Average Exercise Price
Outstanding as of December 31, 2025	36,376,041	$	7.38
Granted	10,545,951	3.50
Exercised	(443,561)	3.49
Forfeited	(1,372,144)	6.98
Outstanding as of June 30, 2026	45,106,287	$	6.53
Options exercisable as of June 30, 2026	21,588,549	$	9.40

The following table summarizes the Company’s RSU activity under the 2020 Plan since December 31, 2025:


	Number of Shares	Weighted- Average Grant Date Fair Value
Outstanding as of December 31, 2025	8,837,384	$	4.75
Granted	4,126,574	3.45
Vested and settled	(2,562,972)	5.56
Forfeited	(559,646)	4.36
Outstanding as of June 30, 2026	9,841,340	$	4.02

As of June 30, 2026, the number of shares available for issuance under the 2020 Plan was 34,201,079, which includes awards granted and outstanding under the Pre-IPO Plan that are forfeited after December 10, 2020.

Stock-based compensation was classified in the condensed consolidated statements of loss and comprehensive loss as follows:


	Three months ended June 30,				Six months ended June 30,
	2025		2026		2025		2026
Research and development expenses	$	7,506	$	6,714	$	15,642	$	13,753
Sales, general, and administrative expenses	6,702		5,572		13,351		10,546
	$	14,208	$	12,286	$	28,993	$	24,299